I7P-MC-DSAG - An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507853-13-00

Acronym

I7P-MC-DSAG

Enrollment

605

Registered

2025-02-10

Start date

2025-02-25

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

Proportion of participants who achieve clinical remission at Week 12

Interventions

DRUGEltrekibart

DRUGMirikizumab

DRUG0.9% sodium chloride

DRUGPlacebo for LY3074828 SC Injection

DRUG1mL Prefilled Syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of participants who achieve clinical remission at Week 12	—

Countries

Belgium, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Poland, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026